Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2019-09-13 Regulatory Filings
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
Directors' details update
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from Mereo BioPharma Group plc regarding 'Directors' details - Update'. It provides specific disclosures and corrections regarding the directorships of various board members, which falls under the category of board/management information. While it is distributed via RNS, the content is specifically about management/director disclosures rather than a general regulatory filing or a report publication announcement.
2019-09-13 English
Notice of Results
Report Publication Announcement Classification · 100% confidence The document is an announcement from Mereo BioPharma stating that they will release their interim financial results on a future date (September 17, 2019) and will host a conference call. It does not contain the actual financial results, but rather serves as a notification of the upcoming report and call. Following the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2019-09-10 English
Block listing Interim Review
Regulatory Filings Classification · 98% confidence The document is a 'Block Listing Interim Review' filed by Mereo BioPharma Group plc via the London Stock Exchange's RNS (Regulatory News Service). It provides a periodic update on the status of unallotted securities under a share option plan. While it involves share schemes, it is a standard regulatory disclosure regarding the status of a block listing rather than a direct announcement of a new share issue (SHA) or a buyback (POS). Given it is a routine regulatory update filed through RNS, it fits best under the general Regulatory Filings category.
2019-09-06 English
Mereo announces phase 2b data at ASBMR Meeting
Regulatory Filings Classification · 100% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service). It announces that clinical trial data for the company's drug 'Setrusumab' has been selected for a presentation at an upcoming medical conference. As this is a general regulatory announcement regarding company operations and clinical progress that does not fit into specific categories like financial reports or shareholder voting, it is classified as a Regulatory Filing (RNS).
2019-09-04 English
FORM 6-K
Board/Management Information Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo BioPharma Group Plc, with the SEC. It reports the entry into an amended and restated employment agreement with an executive, John Richard, including details about his role, compensation, and termination provisions. The document is primarily an announcement of a management employment agreement and does not contain financial statements or detailed financial analysis. It is not a full annual or interim report, nor an earnings release or audit report. The content fits best under Board/Management Information (MANG) as it relates to changes in senior management employment terms. The document length is 3811 characters, which is consistent with a detailed announcement rather than a full report.
2019-09-03 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a formal notification of share purchases by company directors and persons discharging managerial responsibilities (PDMRs), specifically Charles Sermon, Denise Scots-Knight, and John Richard. It explicitly references the EU Market Abuse Regulation and provides the required disclosure tables for insider transactions. This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2019-08-16 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.